Defining Severity of Hemophilia: More than Factor Levels

Abstract

Patients with severe hemophilia generally exhibit a severe bleeding phenotype with bleeding into joints or muscles at an early age. Although the severity and frequency of bleeding symptoms correlate with the residual factor VIII/IX (FVIII/IX) activity in the plasma, a considerable variability in bleeding pattern, FVIII/IX concentrate utilization, and joint damage has been observed. A subset of 10 to 15% of patients with severe hemophilia A shows a milder disease phenotype with significantly reduced frequencies of spontaneous bleeding and lower requirements for factor concentrate. This mitigated clinical phenotype is determined by the underlying mutations in the F8/F9 genes, genetic alterations and polymorphisms in other genes of the hemostasis system, differences in inflammatory and immune response genes, limitations in laboratory diagnostics, as well as environmental factors. Identification of disease-modifying factors in hemophilia may influence treatment decisions, such as starting and tailoring prophylaxis according to the specific clinical phenotype, rather than just the laboratory-defined degree of severity. This review focuses on the current information of factors mitigating the clinical presentation of hemophilia and contributing to its high phenotypic heterogeneity.

Keywords

hemophilia - phenotype heterogeneity - factor FVIII/IX levels

• References

• 1 Biggs R, MacFarlane RG. Haemophilia and related conditions: a survey of 187 cases. Br J Haematol 1958; 4 (1) 1-27
• 2 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
• 3 Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008; 34 (1) 128-141 Review.
• 4 Molho P, Rolland N, Lebrun T , et al; The French Study Group. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. [e-mail] Haemophilia 2000; 6 (1) 23-32
• 5 Aledort LM, Haschmeyer RH, Pettersson H. The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (4) 391-399
• 6 Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361 (9371) 1801-1809
• 7 Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24 (5) 539-551
• 8 Fischer K, van der Bom JG, Mauser-Bunschoten EP , et al. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84 (6) 977-980
• 9 Grünewald M, Siegemund A, Grünewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8 (6) 768-775
• 10 Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among “severe” hemophiliacs with a “milder” bleeding diathesis. Thromb Haemost 1995; 74 (5) 1255-1258
• 11 Shetty S, Vora S, Kulkarni B , et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138 (4) 541-544
• 12 F8 HAMSTeRS mutation database. http://europium.csc.mrc.ac.uk . Accessed December 3, 2009
• 13 F9 mutation database. http://www.kcl.ac.uk/ip/petergreen/haemBdatabase. html . Accessed December 3, 2009.
• 14 Santagostino E, Mancuso ME, Tripodi A , et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (4) 737-743
• 15 Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian Jr HH, Antonarakis SE. Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet 1997; 60 (3) 565-573
• 16 Oldenburg J, Schröder J, Schmitt C, Brackmann HH, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998; 79 (2) 452-453
• 17 Castaman G, Giacomelli SH, Mancuso ME, Sanna S, Santagostino E, Rodeghiero F. F8 mRNA studies in haemophilia A patients with different splice site mutations. Haemophilia 2010; 16 (5) 786-790
• 18 Verbruggen B, Meijer P, Novákova I, Van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia 2008; 14 (Suppl. 03) 76-82
• 19 Lippi G, Franchini M, Favaloro EJ. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. Blood Coagul Fibrinolysis 2009; 20 (1) 1-3
• 20 Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs—characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 1988; 59 (2) 202-206
• 21 Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87 (4) 846-848
• 22 Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94 (2) 400-406
• 23 Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954—>Leu substitution in the factor VIII A3 domain. Br J Haematol 1999; 105 (4) 1123-1126
• 24 Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A. Mutations in the FVIII gene in seven families with mild haemophilia A. Br J Haematol 1997; 96 (2) 426-427
• 25 Schwaab R, Oldenburg J, Kemball-Cook G , et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109 (3) 523-528
• 26 Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010; 30 (4) 207-211
• 27 Nesbitt IM, Hinks JL, Sampson B , et al. Discrepant one and two stage FVIII assays are very common in mild haemophilia A: correlation with FVIII gene mutations. Thromb Haemost 2001; (Suppl): OC195 (abstract)
• 28 Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93 (1) 176-183
• 29 Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97 (3) 685-691
• 30 Roelse JC, de Laaf RTM, Mertens K, van Mourik JA, Oldenburg J, Voorberg J. Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a Glu720 Lys substitution in factor VIII. Thromb Haemost 1999; ;Suppl:Abstract 5
• 31 Goodeve AC, Hinks JL, Nesbitt IM , et al. Unusual discrepant factor VIII:C assays in haemophilia A patients with Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost 2001; ;Suppl:Abstract P1370
• 32 Mumford AD, Laffan M, O'Donnell J , et al. A Tyr346—>Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118 (2) 589-594
• 33 Cid AR, Calabuig M, Cortina V , et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14 (5) 1049-1054
• 34 Jacquemin M, De Maeyer M, D'Oiron R, Lavend'Homme R, Peerlinck K, Saint-Remy JM. Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost 2003; 1 (3) 456-463
• 35 Franchini M, Montagnana M, Targher G , et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009; 35 (3) 307-312
• 36 Nichols WC, Amano K, Cacheris PM , et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88 (4) 1183-1187
• 37 Lee DH, Walker IR, Teitel J , et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83 (3) 387-391
• 38 Vezendi K, Tápai K, Erdödi E , et al. Thrombophilic markers in patients with congenital bleeding disorders. Haematologia (Budap) 2002; 32 (4) 467-473
• 39 Escuriola Ettingshausen C, Halimeh S, Kurnik K , et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85 (2) 218-220
• 40 Vianello F, Belvini D, Dal Bello F , et al. Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)—>T) and heterozygous factor V Leiden. Haemophilia 2001; 7 (5) 511-514
• 41 Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001; 7 (1) 9-12
• 42 López-Jiménez JJ, Beltrán-Miranda CP, Mantilla-Capacho JM, Esparza-Flores MA, López González LC, Jaloma-Cruz AR. Clinical variability of haemophilia A and B in Mexican families by factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T/A1298C. Haemophilia 2009; 15 (6) 1342-1345
• 43 Kurnik K, Kreuz W, Horneff S , et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children—results of a multicenter studys. Haematologica 2007; 92 (7) 982-985
• 44 Tizzano EF, Soria JM, Coll I , et al. The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002; 87 (3) 279-285
• 45 Arruda VR, Annichino-Bizzacchi JM, Antunes SV, Costa FF. Association of severe hemophilia A and factor V Leiden: report of three cases. Haemophilia 1996; 2: 51-53
• 46 Petkova R, Chakarov S, Horvath A, Ganev V, Kremensky I. Coexistence of a common prothrombotic risk factor and hemophilia in the Bulgarian hemophilic population: genotype/phenotype correlations. Balkan J Med Genet 2001; 4: 37-40
• 47 Ahmed R, Kannan M, Choudhry VP, Saxena R. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?. Thromb Res 2003; 109 (1) 71-72
• 48 Beltrán-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11 (4) 326-334
• 49 Araújo F, Fraga M, Henriques I , et al. The clinical phenotype modulation of haemophilia by prothrombotic gene mutations. Haemophilia 2003; 9 (2) 235-236
• 50 Ar MC, Baykara O, Buyru AN, Baslar Z. The impact of prothrombotic mutations on factor consumption in adult patients with severe hemophilia. Clin Appl Thromb Hemost 2009; 15 (6) 660-665
• 51 Sanna V, Zarrilli F, Nardiello P , et al. Mutational spectrum of F8 gene and prothrombotic gene variants in haemophilia A patients from Southern Italy. Haemophilia 2008; 14 (4) 796-803
• 52 Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6 (7) 1113-1121
• 53 Bassus S, Wegert W, Krause M , et al. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Platelets 2006; 17 (6) 378-384
• 54 Schlachterman A, Schuettrumpf J, Liu JH , et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005; 3: 2730-2737
• 55 Nowak-Göttl U, Escuriola C, Kurnik K , et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?. Hamostaseologie 2003; 23 (1) 36-40
• 56 van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92 (2) 305-310
• 57 Jayandharan GR, Nair SC, Poonnoose PM , et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia 2009; 15 (6) 1228-1236
• 58 Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86 (4) 1035-1039
• 59 Yee DL. Platelets as modifiers of clinical phenotype in hemophilia. ScientificWorldJournal 2006; 6: 661-668 Review
• 60 Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90 (5) 781-786
• 61 Smith PS, Baglini R, Meissner GF. The prolonged bleeding time in hemophilia A: comparison of two measuring technics and clinical associations. Am J Clin Pathol 1985; 83 (2) 211-215
• 62 Walsh PN, Rainsford SG, Biggs R. Platelet coagulant activities and clinical severity in haemophilia. Thromb Diath Haemorrh 1973; 29 (3) 722-729
• 63 Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005; 130 (5) 653-661
• 64 Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96 (5) 553-561
• 65 Chitlur M, Warrier I, Rajpurkar M , et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142 (2) 250-256
• 66 Shima M, Matsumoto T, Fukuda K , et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87 (3) 436-441
• 67 Dargaud Y, Béguin S, Lienhart A , et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93 (3) 475-480
• 68 Dargaud Y, Negrier C. Individually tailored prophylaxis in patients with severe hemophilia. J Coagulation Disord 2010; 2: 11-17
• 69 Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 742-752
• 70 Mezzano D, Quiroga T, Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost 2009; 35 (2) 242-254 Review
• 71 Ingerslev J, Poulsen LH, Sørensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9 (4) 348-352
• 72 Oldenburg J, Schröder J, Schmitt C, Brackmann HH, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype. Thromb Haemost 1998; 79 (2) 452-453
• 73 Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thromb Res 2012; 130 (1) 1-6
• 74 Fischer K, van der Bom JG, Mauser-Bunschoten EP , et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7 (5) 446-452
• 75 van Dijk K, van der Bom JG, Lenting PJ , et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90 (4) 494-498
• 76 Fischer K, van der Bom JG, Mauser-Bunschoten EP , et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99 (7) 2337-2341
• 77 Berntorp E. Prophylactic therapy for haemophilia: early experience. Haemophilia 2003; 9 (Suppl. 01) 5-9 , discussion 9
• 78 Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105 (4) 1109-1113
• 79 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
• 80 Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia 2005; 11 (3) 227-232
• 81 Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 03) S166-S170
• 82 Den Uijl IE, Mauser Bunschoten EP, Roosendaal G , et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia 2011; 17 (6) 849-853
• 83 Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18 (1) 63-68
• 84 De la Corte-Rodriguez H, Rodriguez-Merchan EC, Jimenez-Yuste V. Radiosynovectomy in hemophilia: quantification of its effectiveness through the assessment of 10 articular parameters. J Thromb Haemost 2011; 9 (5) 928-935
• 85 Decker JL, Malone DG, Haraoui B , et al. NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med 1984; 101 (6) 810-824
• 86 Klimiuk PA, Goronzy JJ, Björ nsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151 (5) 1311-1319
• 87 Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8 (9) 1895-1902
• 88 Rodriguez-Merchan EC. Haemophilic synovitis: basic concepts. Haemophilia 2007; 13 (Suppl. 03) 1-3
• 89 Roosendaal G, Mauser-Bunschoten EP, De Kleijn P , et al. Synovium in haemophilic arthropathy. Haemophilia 1998; 4 (4) 502-505
• 90 Tagariello G, di Giovine FS. Interleukin-1 in haemophilic arthritis. Thromb Haemost 1996; 75: 979-980
• 91 Hooiveld M, Roosendaal G, Wenting M, van den Berg M, Bijlsma J, Lafeber F. Short-term exposure of cartilage to blood results in chondrocyte apoptosis. Am J Pathol 2003; 162 (3) 943-951
• 92 Hooiveld MJ, Roosendaal G, van den Berg HM, Bijlsma JW, Lafeber FP. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology (Oxford) 2003; 42 (6) 784-790
• 93 Øvlisen K, Kristensen AT, Jensen AL, Tranholm M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 2009; 15 (3) 802-810
• 94 Poli F, Boschiero L, Giannoni F , et al. Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation. Cytokine 2000; 12 (12) 1778-1783
• 95 Vinasco J, Beraún Y, Nieto A , et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49 (1) 74-78
• 96 Huizinga TW, Keijsers V, Yanni G , et al. Are differences in interleukin 10 production associated with joint damage?. Rheumatology (Oxford) 2000; 39 (11) 1180-1188
• 97 Barnes C, Blanchette V, Lillicrap D , et al. Different clinical phenotype in triplets with haemophilia A. Haemophilia 2007; 13 (2) 202-205
• 98 Sahyoun NR, Hochberg MC, Helmick CG, Harris T, Pamuk ER. Body mass index, weight change, and incidence of self-reported physician-diagnosed arthritis among women. Am J Public Health 1999; 89 (3) 391-394